Ustekinumab Rivals Face Exclusion Until 2025
J&J Believes Stelara Will Not Face Biosimilar Competition This Year Or Next
Executive Summary
Speaking during the firm’s Q2 results call, J&J management has indicated that it does not expect biosimilar competition to Stelara to hit the market until at least 2025.